These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 35779821)
21. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353 [TBL] [Abstract][Full Text] [Related]
22. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930 [TBL] [Abstract][Full Text] [Related]
23. CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells. Kim JH; Lee SJ; Kang KW; Lee BH; Park Y; Kim BS Biochem Pharmacol; 2021 Aug; 190():114658. PubMed ID: 34146540 [TBL] [Abstract][Full Text] [Related]
25. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179 [TBL] [Abstract][Full Text] [Related]
26. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors. Singh VK; Chang HH; Kuo CC; Shiao HY; Hsieh HP; Coumar MS J Biomol Struct Dyn; 2017 Jun; 35(8):1833-1848. PubMed ID: 27353341 [TBL] [Abstract][Full Text] [Related]
27. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells. He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies. Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095 [TBL] [Abstract][Full Text] [Related]
29. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study. Kumar H; Raj U; Gupta S; Varadwaj PK J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578 [TBL] [Abstract][Full Text] [Related]
30. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603 [TBL] [Abstract][Full Text] [Related]
31. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells. Elgehama A; Chen W; Pang J; Mi S; Li J; Guo W; Wang X; Gao J; Yu B; Shen Y; Xu Q Cancer Lett; 2016 Mar; 372(1):82-8. PubMed ID: 26721204 [TBL] [Abstract][Full Text] [Related]
32. Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation. Shen Q; Liu S; Chen Y; Yang L; Chen S; Wu X; Li B; Lu Y; Zhu K; Li Y J Hematol Oncol; 2013 Sep; 6():64. PubMed ID: 24004697 [TBL] [Abstract][Full Text] [Related]
34. Targeted drugs in chronic myeloid leukemia. Gora-Tybor J; Robak T Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651 [TBL] [Abstract][Full Text] [Related]
35. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation. Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100 [TBL] [Abstract][Full Text] [Related]
36. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. Aranda-Tavío H; Recio C; Martín-Acosta P; Guerra-Rodríguez M; Brito-Casillas Y; Blanco R; Junco V; León J; Montero JC; Gandullo-Sánchez L; McNaughton-Smith G; Zapata JM; Pandiella A; Amesty A; Estévez-Braun A; Fernández-Pérez L; Guerra B Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells. Roy M; Sarkar R; Mukherjee A; Mukherjee S Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889 [TBL] [Abstract][Full Text] [Related]
38. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells. Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514 [TBL] [Abstract][Full Text] [Related]
39. Research Status, Synthesis and Clinical Application of Recently Marketed and Clinical BCR-ABL Inhibitors. Xu XL; Cao YJ; Zhang W; Rao GW Curr Med Chem; 2022; 29(17):3050-3078. PubMed ID: 34636293 [TBL] [Abstract][Full Text] [Related]
40. Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells. Chiarenza A; Manetti F; Petricci E; Ruat M; Naldini A; Taddei M; Carraro F PLoS One; 2016; 11(3):e0149919. PubMed ID: 26934052 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]